Clinical Trials /

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01643499

Description:

This study is being done to determine the dose of a chemotherapy drug (irinotecan [irinotecan hydrochloride]) that can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs often used to treat gastrointestinal cancer, which consists of 5-FU (fluorouracil), leucovorin (leucovorin calcium), irinotecan and oxaliplatin and is known as "FOLFIRINOX". FOLFIRINOX is a current drug therapy combination (or regimen) used for people with advanced pancreatic cancer, although this combination is not Food and Drug Administration (FDA) approved for this indication. FOLFIRINOX was recently shown in a separate clinical trial to increase survival compared to another commonly used drug in pancreatic cancer called gemcitabine. FOLFIRINOX is also a reasonable regimen for those with other advanced cancers of the gastrointestinal tract, including colon cancer, rectal cancer, esophagus cancer, stomach cancer, gall bladder cancer, bile duct cancer, ampullary cancer, and cancers with an unknown primary location. The best dose of irinotecan to use in FOLFIRINOX is not known. This study will analyze one gene (uridine 5'-diphospho [UDP] glucuronosyltransferase 1 family, polypeptide A1 [UGT1A1] gene) of subjects for the presence of an alteration in that gene, which may affect how the body handles irinotecan. Genes help determine some of the investigators individual characteristics, such as eye color, height and skin tone. Genes may also determine why people get certain diseases and how medicines may affect them. The result of the genetic analysis will divide subjects into one of three groups: A, B, or C. Group A (approximately 45% of subjects) will receive the standard dose of irinotecan. Group B (approximately 45% of subjects) will receive a lower dose of irinotecan. Group C (approximately 10% of subjects) will receive an even lower dose of irinotecan

Related Conditions:
  • Ampulla of Vater Carcinoma
  • Cholangiocarcinoma
  • Colorectal Adenocarcinoma
  • Digestive System Carcinoma
  • Gallbladder Adenocarcinoma
  • Gastric Adenocarcinoma
  • Pancreatic Adenocarcinoma
Recruiting Status:

Active, not recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
  • Official Title: A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies

Clinical Trial IDs

  • ORG STUDY ID: 12-0033
  • SECONDARY ID: NCI-2012-00585
  • NCT ID: NCT01643499

Conditions

  • Acinar Cell Adenocarcinoma of the Pancreas
  • Adenocarcinoma of the Gallbladder
  • Adenocarcinoma of Unknown Primary
  • Adult Primary Cholangiocellular Carcinoma
  • Advanced Adult Primary Liver Cancer
  • Cholangiocarcinoma of the Extrahepatic Bile Duct
  • Cholangiocarcinoma of the Gallbladder
  • Diffuse Adenocarcinoma of the Stomach
  • Duct Cell Adenocarcinoma of the Pancreas
  • Intestinal Adenocarcinoma of the Stomach
  • Localized Unresectable Adult Primary Liver Cancer
  • Metastatic Carcinoma of Unknown Primary
  • Metastatic Extrahepatic Bile Duct Cancer
  • Mixed Adenocarcinoma of the Stomach
  • Mucinous Adenocarcinoma of the Colon
  • Mucinous Adenocarcinoma of the Rectum
  • Newly Diagnosed Carcinoma of Unknown Primary
  • Signet Ring Adenocarcinoma of the Colon
  • Signet Ring Adenocarcinoma of the Rectum
  • Stage III Pancreatic Cancer
  • Stage IIIA Colon Cancer
  • Stage IIIA Gallbladder Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIA Rectal Cancer
  • Stage IIIB Colon Cancer
  • Stage IIIB Gallbladder Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIB Rectal Cancer
  • Stage IIIC Colon Cancer
  • Stage IIIC Gastric Cancer
  • Stage IIIC Rectal Cancer
  • Stage IV Gastric Cancer
  • Stage IV Pancreatic Cancer
  • Stage IVA Colon Cancer
  • Stage IVA Gallbladder Cancer
  • Stage IVA Rectal Cancer
  • Stage IVB Colon Cancer
  • Stage IVB Gallbladder Cancer
  • Stage IVB Rectal Cancer
  • Unresectable Extrahepatic Bile Duct Cancer

Interventions

DrugSynonymsArms
oxaliplatin1-OHP, Dacotin, Dacplat, Eloxatin, L-OHPTreatment (mFOLFIRINOX)
irinotecan hydrochlorideCampto, Camptosar, CPT-11, irinotecan, U-101440ETreatment (mFOLFIRINOX)
leucovorin calciumCF, CFR, LVTreatment (mFOLFIRINOX)
fluorouracil5-fluorouracil, 5-Fluracil, 5-FUTreatment (mFOLFIRINOX)

Purpose

This study is being done to determine the dose of a chemotherapy drug (irinotecan [irinotecan hydrochloride]) that can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs often used to treat gastrointestinal cancer, which consists of 5-FU (fluorouracil), leucovorin (leucovorin calcium), irinotecan and oxaliplatin and is known as "FOLFIRINOX". FOLFIRINOX is a current drug therapy combination (or regimen) used for people with advanced pancreatic cancer, although this combination is not Food and Drug Administration (FDA) approved for this indication. FOLFIRINOX was recently shown in a separate clinical trial to increase survival compared to another commonly used drug in pancreatic cancer called gemcitabine. FOLFIRINOX is also a reasonable regimen for those with other advanced cancers of the gastrointestinal tract, including colon cancer, rectal cancer, esophagus cancer, stomach cancer, gall bladder cancer, bile duct cancer, ampullary cancer, and cancers with an unknown primary location. The best dose of irinotecan to use in FOLFIRINOX is not known. This study will analyze one gene (uridine 5'-diphospho [UDP] glucuronosyltransferase 1 family, polypeptide A1 [UGT1A1] gene) of subjects for the presence of an alteration in that gene, which may affect how the body handles irinotecan. Genes help determine some of the investigators individual characteristics, such as eye color, height and skin tone. Genes may also determine why people get certain diseases and how medicines may affect them. The result of the genetic analysis will divide subjects into one of three groups: A, B, or C. Group A (approximately 45% of subjects) will receive the standard dose of irinotecan. Group B (approximately 45% of subjects) will receive a lower dose of irinotecan. Group C (approximately 10% of subjects) will receive an even lower dose of irinotecan

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the dose-limiting toxicity (DLT) rate in cycle #1 in each of two UGT1A1
      genotype groups (*1*1, *1*28) using genotype-guided dosing of irinotecan as part of the
      modified (m) FOLFIRINOX regimen.

      SECONDARY OBJECTIVES:

      I. To determine the cumulative dose intensity of irinotecan achieved in each genotype group.

      II. To determine the response rates by Response Evaluation Criteria in Solid Tumors (RECIST)
      (version 1.1) for each different disease (pancreatic cancer, biliary cancers, gastric
      cancer, colorectal cancer, adenocarcinoma of unknown primary) treated in the study.

      OUTLINE:

      Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV
      over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46
      hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence
      of disease progression or unacceptable toxicity.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (mFOLFIRINOX)ExperimentalPatients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • oxaliplatin
  • irinotecan hydrochloride
  • leucovorin calcium
  • fluorouracil

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically or cytologically confirmed locally advanced or metastatic pancreatic
             adenocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma,
             cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma
             of unclear primary (with a gastrointestinal primary suspected), or other primary
             gastrointestinal malignancy for which the treating physician feels that mFOLFIRINOX
             is a reasonable therapeutic option.

          -  Amendment (January 2014): only subjects with the following histologies will be
             eligible

        Cohort # 1 (pancreatic cohort): locally advanced or metastatic pancreatic adenocarcinoma
        (19 subjects evaluable for the primary endpoint after the amendment)

        Cohort #2 (biliary tract cohort): locally advanced or metastatic cholangiocarcinoma, gall
        bladder adenocarcinoma, or ampullary carcinoma (19 subjects evaluable for the primary
        endpoint after the amendment). Patients with adenocarcinoma of unclear primary that are
        most likely of biliary tract origin (in the opinion of the treating physician) will also
        be allowed on this cohort.

          -  Patients with a history of obstructive jaundice due to the primary tumor must have a
             metal biliary stent in place,

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1,

          -  Life expectancy > 3 months,

          -  Absolute neutrophil count (ANC) >= l500/ul,

          -  Hemoglobin >= 9g/dL,

          -  Platelets >= 100,000/ ul,

          -  Total bilirubin < 1.5 x upper limit of normal,

          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate
             transaminase (SGPT) < 2.5 x upper limit of normal for patients without liver
             metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver
             metastases,

          -  Creatinine =< 1.5 x upper limit of normal,

          -  Measurable or non-measurable disease will be allowed,

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation, up until 30 days after final study
             treatment; should a woman become pregnant or suspect that she is pregnant while
             participating in this study, she should inform her treating physician immediately,

          -  Patients taking substrates, inhibitors, or inducers of Cytochrome P450 3A4 (CYP3A4)
             should be encouraged to switch to alternative drugs whenever possible, given the
             potential for drug-drug interactions with irinotecan

          -  Signed informed consent.

        Exclusion Criteria:

          -  Prior chemotherapy or radiation therapy for any cancer,

          -  Inflammatory bowel disease (Crohn's disease, ulcerative colitis),

          -  Diarrhea, grade 1 or greater by the National Cancer Institute Common Terminology
             Criteria for Adverse Events (NCI-CTCAE, v. 4.0); pancreatic cancer patients with
             clinical evidence of pancreatic insufficiency must be taking pancreatic enzyme
             replacement,

          -  Neuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0,

          -  Documented brain metastases,

          -  Serious underlying medical or psychiatric illnesses that would, in the opinion of the
             treating physician, substantially increase the risk for complications related to
             treatment,

          -  Active uncontrolled bleeding,

          -  Pregnancy or breastfeeding,

          -  Major surgery within 4 weeks,

          -  Previous or concurrent malignancy, except for adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the
             patient has been previously treated and the lifetime recurrence risk is less than
             30%,

          -  Patients with any polymorphism in UGT1A1 other than *1 or *28.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28)
Time Frame:4 weeks
Safety Issue:
Description:To show that the DLT rate is less than 33% with at least 70-80% confidence, which is comparable to the standard 3+3 phase I design with 0 out of 3 or 1 out of 6 patients experiencing a DLT.

Secondary Outcome Measures

Measure:Response rates (by RECIST 1.1) for patients with each different type of gastrointestinal malignancy
Time Frame:Up to 1 year
Safety Issue:
Description:
Measure:Cumulative dose intensity of irinotecan hydrochloride
Time Frame:Up to 1 year
Safety Issue:
Description:

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:University of Chicago

Last Updated

April 12, 2017